Organization
University of Washington, Swedish Medical Center and Providence St. Joseph Health, Seattle, United States of America
1 abstract
Abstract
BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDYOrg: Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America, University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, United Kingdom, University of Rochester, Department of Medicine, Rochester, United States of America, University of Washington, Swedish Medical Center and Providence St. Joseph Health, Seattle, United States of America, Amsterdam Rheumatology & Clinical Immunology Center, Department of Clinical Immunology & Rheumatology, Amsterdam, Netherlands,